Identifying the Etiology: A Systematic Approach Using Delayed-Enhancement Cardiovascular Magnetic Resonance

Heart Failure Clinics

Volumn 5, Issue 3, 2009, Pages 349-367

  Senthilkumar, Annamalai ^a   Majmudar, Maulik D ^a   Shenoy, Chetan ^a   Kim, Han W ^a   Kim, Raymond J ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Cardiomyopathy; Cardiovascular magnetic resonance; Delayed enhancement imaging; Heart failure; Ischemic; Non ischemic

Indexed keywords

DIPYRIDAMOLE; GADOLINIUM CHELATE; TRASTUZUMAB;

AMYLOIDOSIS; CARDIOMYOPATHY; CARDIOVASCULAR RISK; CHAGAS DISEASE; CONGESTIVE CARDIOMYOPATHY; EXERCISE TEST; HEART INFARCTION; HUMAN; IMAGE ENHANCEMENT; ISCHEMIC HEART DISEASE; MYOCARDITIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; REVIEW; SARCOIDOSIS; SYSTEMIC SCLEROSIS; TAKOTSUBO CARDIOMYOPATHY;

ALGORITHMS; CARDIOMYOPATHIES; CORONARY ARTERY DISEASE; HUMANS; MAGNETIC RESONANCE IMAGING; MYOCARDIAL ISCHEMIA;

EID: 67649283806     PISSN: 15517136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hfc.2009.02.009     Document Type: Review

References (93)

1. Richardson P., McKenna W., Bristow M., et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. Circulation 93 5 (1996) 841-842
2. Maron B.J., Towbin J.A., Thiene G., et al. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation 113 14 (2006) 1807-1816
3. Alderman E.L., Fisher L.D., Litwin P., et al. Results of coronary artery surgery in patients with poor left ventricular function (CASS). Circulation 68 4 (1983) 785-795
4. Felker G.M., Shaw L.K., and O'Connor C.M. A standardized definition of ischemic cardiomyopathy for use in clinical research. J Am Coll Cardiol 39 2 (2002) 210-218
5. Packer M., Coats A.J., Fowler M.B., et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344 22 (2001) 1651-1658
6. Felker G.M., Thompson R.E., Hare J.M., et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med 342 15 (2000) 1077-1084
7. Kim R.J., Fieno D.S., Parrish T.B., et al. Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. Circulation 100 19 (1999) 1992-2002
8. Mahrholdt H., Goedecke C., Wagner A., et al. Cardiovascular magnetic resonance assessment of human myocarditis: a comparison to histology and molecular pathology. Circulation 109 10 (2004) 1250-1258
9. Moon J.C., Reed E., Sheppard M.N., et al. The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol 43 12 (2004) 2260-2264
10. Wu E., Judd R.M., Vargas J.D., et al. Visualisation of presence, location, and transmural extent of healed Q-wave and non-Q-wave myocardial infarction. Lancet 357 9249 (2001) 21-28
11. Wagner A., Mahrholdt H., Thomson L., et al. Effects of time, dose, and inversion time for acute myocardial infarct size measurements based on magnetic resonance imaging-delayed contrast enhancement. J Am Coll Cardiol 47 10 (2006) 2027-2033
12. Ricciardi M.J., Wu E., Davidson C.J., et al. Visualization of discrete microinfarction after percutaneous coronary intervention associated with mild creatine kinase-MB elevation. Circulation 103 23 (2001) 2780-2783
13. Uretsky B.F., Thygesen K., Armstrong P.W., et al. Acute coronary findings at autopsy in heart failure patients with sudden death: results from the assessment of treatment with lisinopril and survival (ATLAS) trial. Circulation 102 6 (2000) 611-616
14. Corya B., Feigenbaum H., Rasmussen S., et al. Echocardiographic features of congestive cardiomyopathy compared with normal subjects and patients with coronary artery disease. Circulation 49 6 (1974) 1153-1159
15. Wallis D.E., O'Connell J.B., Henkin R.E., et al. Segmental wall motion abnormalities in dilated cardiomyopathy: a common finding and good prognostic sign. J Am Coll Cardiol 4 4 (1984) 674-679
16. Glamann D.B., Lange R.A., Corbett J.R., et al. Utility of various radionuclide techniques for distinguishing ischemic from non-ischemic dilated cardiomyopathy. Arch Intern Med 152 4 (1992) 769-772
17. Rahman J.E., Helou E.F., Gelzer-Bell R., et al. Noninvasive diagnosis of biopsy-proven cardiac amyloidosis. J Am Coll Cardiol 43 3 (2004) 410-415
18. Kubo N., Morimoto S., Hiramitsu S., et al. Feasibility of diagnosing chronic myocarditis by endomyocardial biopsy. Heart Vessels 12 4 (1997) 167-170
19. Hauck A.J., Kearney D.L., and Edwards W.D. Evaluation of postmortem endomyocardial biopsy specimens from 38 patients with lymphocytic myocarditis: implications for role of sampling error. Mayo Clin Proc 64 10 (1989) 1235-1245
20. Kronmal R.A., McClelland R.L., Detrano R., et al. Risk factors for the progression of coronary artery calcification in asymptomatic subjects: results from the Multi-Ethnic Study of Atherosclerosis (MESA). Circulation 115 21 (2007) 2722-2730
21. Kim R.J., Wu E., Rafael A., et al. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med 343 20 (2000) 1445-1453
22. Shah D.J., Judd R.M., and Kim R.J. Myocardial viability. In: Edelman R.R., Hesselink J.R., and Zlatkin M.B. (Eds). Clinical magnetic resonance imaging. 3rd edition (2006), Elsevier, New York
23. Kim R.J., Elliott M.D., and Judd R.M. Assessment of myocardial viability by contrast enhancement. In: Higgins C.B., and de Roos A. (Eds). MRI and CT of thecardiovascular system. 2nd edition (2005), Lippincott Williams & Wilkins, Philadelphia
24. Koenig S.H., Spiller M., Brown III R.D., et al. Relaxation of water protons in the intra- and extracellular regions of blood containing Gd(DTPA). Magn Reson Med 3 5 (1986) 791-795
25. Polimeni P.I. Extracellular space and ionic distribution in rat ventricle. Am J Physiol 227 3 (1974) 676-683
26. Rehwald W.G., Fieno D.S., Chen E.L., et al. Myocardial magnetic resonance imaging contrast agent concentrations after reversible and irreversible ischemic injury. Circulation 105 2 (2002) 224-229
27. Reimer K.A., Lowe J.E., Rasmussen M.M., et al. The wavefront phenomenon of ischemic cell death. 1. Myocardial infarct size vs duration of coronary occlusion in dogs. Circulation 56 5 (1977) 786-794
28. Bello D., Shah D.J., Farah G.M., et al. Gadolinium cardiovascular magnetic resonance predicts reversible myocardial dysfunction and remodeling in patients with heart failure undergoing beta-blocker therapy. Circulation 108 16 (2003) 1945-1953
29. Casolo G., Minneci S., Manta R., et al. Identification of the ischemic etiology of heart failure by cardiovascular magnetic resonance imaging: diagnostic accuracy of late gadolinium enhancement. Am Heart J 151 1 (2006) 101-108
30. Soriano C.J., Ridocci F., Estornell J., et al. Noninvasive diagnosis of coronary artery disease in patients with heart failure and systolic dysfunction of uncertain etiology, using late gadolinium-enhanced cardiovascular magnetic resonance. J Am Coll Cardiol 45 5 (2005) 743-748
31. Schuster E.H., and Bulkley B.H. Ischemic cardiomyopathy: a clinicopathologic study of fourteen patients. Am Heart J 100 4 (1980) 506-512
32. Boucher C.A., Fallon J.T., Johnson R.A., et al. Cardiomyopathic syndrome caused by coronary artery disease. III: Prospective clinicopathological study of its prevalence among patients with clinically unexplained chronic heart failure. Br Heart J 41 5 (1979) 613-620
33. Roberts W.C., Siegel R.J., and McManus B.M. Idiopathic dilated cardiomyopathy: analysis of 152 necropsy patients. Am J Cardiol 60 16 (1987) 1340-1355
34. McCrohon J.A., Moon J.C., Prasad S.K., et al. Differentiation of heart failure related to dilated cardiomyopathy and coronary artery disease using gadolinium-enhanced cardiovascular magnetic resonance. Circulation 108 1 (2003) 54-59
35. Topol E.J., and Yadav J.S. Recognition of the importance of embolization in atherosclerotic vascular disease. Circulation 101 5 (2000) 570-580
36. Arroyo L.H., and Lee R.T. Mechanisms of plaque rupture: mechanical and biologic interactions. Cardiovasc Res 41 2 (1999) 369-375
37. Assomull R.G., Prasad S.K., Lyne J., et al. Cardiovascular magnetic resonance, fibrosis, and prognosis in dilated cardiomyopathy. J Am Coll Cardiol 48 10 (2006) 1977-1985
38. Choudhury L., Mahrholdt H., Wagner A., et al. Myocardial scarring in asymptomatic or mildly symptomatic patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 40 12 (2002) 2156-2164
39. Moon J.C., Sachdev B., Elkington A.G., et al. Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease. Evidence for a disease specific abnormality of the myocardial interstitium. Eur Heart J 24 23 (2003) 2151-2155
40. Rochitte C.E., Oliveira P.F., Andrade J.M., et al. Myocardial delayed enhancement by magnetic resonance imaging in patients with Chagas' disease: a marker of disease severity. J Am Coll Cardiol 46 8 (2005) 1553-1558
41. Mahrholdt H., Wagner A., Deluigi C.C., et al. Presentation, patterns of myocardial damage, and clinical course of viral myocarditis. Circulation 114 15 (2006) 1581-1590
42. Kim R.J., and Judd R.M. Gadolinium-enhanced magnetic resonance imaging in hypertrophic cardiomyopathy: in vivo imaging of the pathologic substrate for premature cardiac death?. J Am Coll Cardiol 41 9 (2003) 1568-1572
43. Shirani J., Freant L.J., and Roberts W.C. Gross and semiquantitative histologic findings in mononuclear cell myocarditis causing sudden death, and implications for endomyocardial biopsy. Am J Cardiol 72 12 (1993) 952-957
44. Moon J.C., Sheppard M., Reed E., et al. The histological basis of late gadolinium enhancement cardiovascular magnetic resonance in a patient with Anderson-Fabry disease. J Cardiovasc Magn Reson 8 3 (2006) 479-482
45. Simonetti O.P., Kim R.J., Fieno D.S., et al. An improved MR imaging technique for the visualization of myocardial infarction. Radiology 218 1 (2001) 215-223
46. Kim R.J., Shah D.J., and Judd R.M. How we perform delayed enhancement imaging. J Cardiovasc Magn Reson 5 3 (2003) 505-514
47. Mahrholdt H., Wagner A., Judd R.M., et al. Delayed enhancement cardiovascular magnetic resonance assessment of non-ischaemic cardiomyopathies. Eur Heart J 26 15 (2005) 1461-1474
48. Bellenger N.G., Burgess M.I., Ray S.G., et al. Comparison of left ventricular ejection fraction and volumes in heart failure by echocardiography, radionuclide ventriculography and cardiovascular magnetic resonance; are they interchangeable?. Eur Heart J 21 16 (2000) 1387-1396
49. Bellenger N.G., Davies L.C., Francis J.M., et al. Reduction in sample size for studies of remodeling in heart failure by the use of cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2 4 (2000) 271-278
50. Kotani J., Mintz G.S., Castagna M.T., et al. Intravascular ultrasound analysis of infarct-related and non-infarct-related arteries in patients who presented with an acute myocardial infarction. Circulation 107 23 (2003) 2889-2893
51. Hunt S.A., Abraham W.T., Chin M.H., et al. ACC/AHA 2005 Guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 112 12 (2005) e154-e235
52. Matoh F., Satoh H., Shiraki K., et al. The usefulness of delayed enhancement magnetic resonance imaging for diagnosis and evaluation of cardiac function in patients with cardiac sarcoidosis. J Cardiol 51 3 (2008) 179-188
53. Wilson J.M., Villareal R.P., Hariharan R., et al. Magnetic resonance imaging of myocardial fibrosis in hypertrophic cardiomyopathy. Tex Heart Inst J 29 3 (2002) 176-180
54. Moon J.C., McKenna W.J., McCrohon J.A., et al. Toward clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance. J Am Coll Cardiol 41 9 (2003) 1561-1567
55. Amano Y., Takayama M., Takahama K., et al. Delayed hyper-enhancement of myocardium in hypertrophic cardiomyopathy with asymmetrical septal hypertrophy: comparison with global and regional cardiac MR imaging appearances. J Magn Reson Imaging 20 4 (2004) 595-600
56. Teraoka K., Hirano M., Ookubo H., et al. Delayed contrast enhancement of MRI in hypertrophic cardiomyopathy. Magn Reson Imaging 22 2 (2004) 155-161
57. Moon J.C., Mogensen J., Elliott P.M., et al. Myocardial late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy caused by mutations in troponin I. Heart 91 8 (2005) 1036-1040
58. Soler R., Rodriguez E., Monserrat L., et al. Magnetic resonance imaging of delayed enhancement in hypertrophic cardiomyopathy: relationship with left ventricular perfusion and contractile function. J Comput Assist Tomogr 30 3 (2006) 412-420
59. Dumont C.A., Monserrat L., Soler R., et al. [Clinical significance of late gadolinium enhancement on cardiovascular magnetic resonance in patients with hypertrophic cardiomyopathy]. Rev Esp Cardiol 60 1 (2007) 15-23 [in Spanish]
60. Matoh F., Satoh H., Shiraki K., et al. Usefulness of delayed enhancement magnetic resonance imaging to differentiate dilated phase of hypertrophic cardiomyopathy and dilated cardiomyopathy. J Card Fail 13 5 (2007) 372-379
61. Melacini P., Corbetti F., Calore C., et al. Cardiovascular magnetic resonance signs of ischemia in hypertrophic cardiomyopathy. Int J Cardiol 128 3 (2008) 364-373
62. Paya E., Marin F., Gonzalez J., et al. Variables associated with contrast-enhanced cardiovascular magnetic resonance in hypertrophic cardiomyopathy: clinical implications. J Card Fail 14 5 (2008) 414-419
63. Suk T., Edwards C., Hart H., et al. Myocardial scar detected by contrast-enhanced cardiac magnetic resonance imaging is associated with ventricular tachycardia in hypertrophic cardiomyopathy patients. Heart Lung Circ 17 5 (2008) 370-374
64. Maceira A.M., Joshi J., Prasad S.K., et al. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation 111 2 (2005) 186-193
65. Perugini E., Rapezzi C., Piva T., et al. Non-invasive evaluation of the myocardial substrate of cardiac amyloidosis by gadolinium cardiac magnetic resonance. Heart 92 3 (2006) 343-349
66. Hosch W., Libicher M., Ley S., et al. [MR imaging in cardiac amyloidosis-morphology, function and late enhancement]. Rofo 180 7 (2008) 639-645 [in German]
67. Vogelsberg H., Mahrholdt H., Deluigi C.C., et al. Cardiovascular magnetic resonance in clinically suspected cardiac amyloidosis: noninvasive imaging compared to endomyocardial biopsy. J Am Coll Cardiol 51 10 (2008) 1022-1030
68. Shimada T., Shimada K., Sakane T., et al. Diagnosis of cardiac sarcoidosis and evaluation of the effects of steroid therapy by gadolinium-DTPA-enhanced magnetic resonance imaging. Am J Med 110 7 (2001) 520-527
69. Smedema J.P., Snoep G., van Kroonenburgh M.P., et al. Evaluation of the accuracy of gadolinium-enhanced cardiovascular magnetic resonance in the diagnosis of cardiac sarcoidosis. J Am Coll Cardiol 45 10 (2005) 1683-1690
70. Tadamura E., Yamamuro M., Kubo S., et al. Effectiveness of delayed enhanced MRI for identification of cardiac sarcoidosis: comparison with radionuclide imaging. AJR Am J Roentgenol 185 1 (2005) 110-115
71. Laissy J.P., Hyafil F., Feldman L.J., et al. Differentiating acute myocardial infarction from myocarditis: diagnostic value of early- and delayed-perfusion cardiac MR imaging. Radiology 237 1 (2005) 75-82
72. Yelgec N.S., Dymarkowski S., Ganame J., et al. Value of MRI in patients with a clinical suspicion of acute myocarditis. Eur Radiol 17 9 (2007) 2211-2217
73. Gutberlet M., Spors B., Thoma T., et al. Suspected chronic myocarditis at cardiac MR: diagnostic accuracy and association with immunohistologically detected inflammation and viral persistence. Radiology 246 2 (2008) 401-409
74. Weidemann F., Breunig F., Beer M., et al. The variation of morphological and functional cardiac manifestation in Fabry disease: potential implications for the time course of the disease. Eur Heart J 26 12 (2005) 1221-1227
75. Beer M., Weidemann F., Breunig F., et al. Impact of enzyme replacement therapy on cardiac morphology and function and late enhancement in Fabry's cardiomyopathy. Am J Cardiol 97 10 (2006) 1515-1518
76. Silva M.C., Meira Z.M., Gurgel Giannetti J., et al. Myocardial delayed enhancement by magnetic resonance imaging in patients with muscular dystrophy. J Am Coll Cardiol 49 18 (2007) 1874-1879
77. Yilmaz A., Gdynia H.J., Baccouche H., et al. Cardiac involvement in patients with Becker muscular dystrophy: new diagnostic and pathophysiological insights by a CMR approach. J Cardiovasc Magn Reson 10 1 (2008) 50
78. Puchalski M.D., Williams R.V., Askovich B., et al. Late gadolinium enhancement: precursor to cardiomyopathy in Duchenne muscular dystrophy?. Int J Cardiovasc Imaging 25 1 (2009) 57-63
79. Sanz J., Dellegrottaglie S., Kariisa M., et al. Prevalence and correlates of septal delayed contrast enhancement in patients with pulmonary hypertension. Am J Cardiol 100 4 (2007) 731-735
80. Tzelepis G.E., Kelekis N.L., Plastiras S.C., et al. Pattern and distribution of myocardial fibrosis in systemic sclerosis: a delayed enhanced magnetic resonance imaging study. Arthritis Rheum 56 11 (2007) 3827-3836
81. Kobayashi H., Yokoe I., Hirano M., et al. Cardiac magnetic resonance imaging with pharmacological stress perfusion and delayed enhancement in asymptomatic patients with systemic sclerosis. J Rheumatol 36 1 (2009) 106-112
82. Nassenstein K., Breuckmann F., Huger M., et al. Detection of myocardial fibrosis in systemic sclerosis by contrast-enhanced magnetic resonance imaging. Rofo 108 12 (2008) 1054-1060
83. Mitchell J.H., Hadden T.B., Wilson J.M., et al. Clinical features and usefulness of cardiac magnetic resonance imaging in assessing myocardial viability and prognosis in Takotsubo cardiomyopathy (transient left ventricular apical ballooning syndrome). Am J Cardiol 100 2 (2007) 296-301
84. Eitel I., Behrendt F., Schindler K., et al. Differential diagnosis of suspected apical ballooning syndrome using contrast-enhanced magnetic resonance imaging. Eur Heart J 29 21 (2008) 2651-2659
85. Mark P.B., Johnston N., Groenning B.A., et al. Redefinition of uremic cardiomyopathy by contrast-enhanced cardiac magnetic resonance imaging. Kidney Int 69 10 (2006) 1839-1845
86. Debl K., Djavidani B., Buchner S., et al. Delayed hyperenhancement in magnetic resonance imaging of left ventricular hypertrophy caused by aortic stenosis and hypertrophic cardiomyopathy: visualisation of focal fibrosis. Heart 92 10 (2006) 1447-1451
87. Wassmuth R., Gobel U., Natusch A., et al. Cardiovascular magnetic resonance imaging detects cardiac involvement in Churg-Strauss syndrome. J Card Fail 14 10 (2008) 856-860
88. Breuckmann F., Nassenstein K., Kondratieva J., et al. MR characterization of cardiac abnormalities in HIV+ individuals with increased BNP levels. Eur J Med Res 12 5 (2007) 185-190
89. Raman S.V., Sparks E.A., Baker P.M., et al. Mid-myocardial fibrosis by cardiac magnetic resonance in patients with lamin A/C cardiomyopathy: possible substrate for diastolic dysfunction. J Cardiovasc Magn Reson 9 6 (2007) 907-913
90. Mouquet F., Lions C., de Groote P., et al. Characterisation of peripartum cardiomyopathy by cardiac magnetic resonance imaging. Eur Radiol 18 12 (2008) 2765-2769
91. Fallah-Rad N., Lytwyn M., Fang T., et al. Delayed contrast enhancement cardiac magnetic resonance imaging in trastuzumab induced cardiomyopathy. J Cardiovasc Magn Reson 10 1 (2008) 5
92. Strach K., Sommer T., Grohe C., et al. Clinical, genetic, and cardiac magnetic resonance imaging findings in primary desminopathies. Neuromuscul Disord 18 6 (2008) 475-482
93. Abdel-Aty H., Siegle N., Natusch A., et al. Myocardial tissue characterization in systemic lupus erythematosus: value of a comprehensive cardiovascular magnetic resonance approach. Lupus 17 6 (2008) 561-567